BioSpecifics Technologies

Tomorrow BioSpecifics Tech. (Nasdaq-BTSC) will hold its annual meeting.  I am a shareholder but will not be able to attend.  However, I still believe that this stock has the potential for a real run from current price levels.  BTSC is the original developer of injectable collangenase.  BTSC has a great relationship with Auxilium  (Nasdaq-AUXL) which provides for substantial royalty payements. In recent days a research report was issued placing a 12-month price target of $40 on the BTSC shares.  In my view, BioSpecifics is very undervalued and the just mentioned price target seems reasonable.

Leave a Reply

Your email address will not be published.